• Molecular NameDeferoxamine
  • SynonymDeferoxamide B; Deferoxamin; Deferoxamine B; Deferoxamine mesylate; Deferoxaminum; Deferrioxamine; Deferrioxamine B; Desferrioxamine; Desferrioxamine B; DF B; DFO; DFOA; DFOM; N-Benzoylferrioxamine B
  • Weight560.693
  • Drugbank_IDDB00746
  • ACS_NO70-51-9
  • Show 3D model
  • LogP (experiment)-0.478
  • LogP (predicted, AB/LogP v2.0)-0.65
  • pkaN/A
  • LogD (pH=7, predicted)-3.51
  • Solubility (experiment)11.8 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)0.25
  • LogSw (predicted, AB/LogsW2.0)8.65
  • Sw (mg/ml) (predicted, ACD/Labs)57.12
  • No.of HBond Donors7
  • No.of HBond Acceptors14
  • No.of Rotatable Bonds23
  • TPSA205.84
  • StatusFDA approved
  • AdministrationOral, IV, IM, SQ
  • PharmacologyA bacterial siderophore produced by the actinobacter Streptomyces pilosus. It has medical applications as a chelating agent used to remove excess iron from the body.
  • Absorption_value2.0
  • Absorption (description)Deferoxamine is rapidly absorbed after intramuscular or subcutaneous administration, but only poorly absorbed from the gastrointestinal tract in the presence of intact mucosa.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding10.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmDeferoxamine is mainly metabolised in the plasma and hepatic metabolism is minimal. A number of metabolites have been isolated but not characterised. Some metabolites of deferoxamine, most notably the product of oxidative deamination, also chelate iron, and thus the antidotal effect of the drug appears unaffected by hepatic metabolism.
  • Half lifeBiphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityNephrotoxicity, ototoxicity and retinal toxicity have been reported following long-term administration for chronic iron overload.
  • LD50 (rat)Intravenous LD50 in mouse, rat, and rabbit is 340 mg/kg, 520 mg/kg, and 600 mg/kg, respectively. Subcutaneous LD50 in mouse and rat is 1600 mg/kg and >1000 mg/kg, respectively. Oral LD50 in mouse and rat is >3000 mg/kg and >1000 mg/kg, respectively.
  • LD50 (mouse)N/A